Latest Administration News

Nexsen Limited is advancing its rapid Group B Streptococcus test, StrepSure®, with a clear FDA submission timeline and early market entries across Asia-Pacific and emerging regions.

Atomo Diagnostics has responded to an ASX price query following unusual trading activity, denying any undisclosed price-sensitive information while acknowledging a related FDA update involving Lumos Diagnostics.

FINEOS Corporation reports robust FY25 financial performance, driven by subscription revenue growth and embedded AI innovations, setting a confident outlook through FY27.

Recce Pharmaceuticals has expanded its intellectual property footprint with a newly granted patent in Brazil, protecting its innovative synthetic anti-infectives against a broad range of infections. This milestone strengthens Recce’s position in one of South America’s largest antibiotic markets.

Coles Group Limited has updated its dividend details, confirming a fully franked 41 cent per share payout for the half-year ending January 2026, alongside a Dividend Reinvestment Plan price set at $21.32.

Radiopharm Theranostics reports promising second interim Phase 2b results for RAD 101, showing 90% concordance with MRI in detecting brain metastases and encouraging sensitivity and specificity trends.

Echo IQ has strengthened its partnership with Mayo Clinic to distribute its AI-driven heart failure diagnostic tool, EchoSolv HF, pending FDA clearance. The expanded agreement offers a scalable commercial pathway across a vast US hospital network.

SQX Resources has addressed an ASX compliance query regarding director Bevan Tarratt’s trading during a closed period, confirming prior board approval and an administrative disclosure error.

Generation Development Group Limited updates its Dividend Reinvestment Plan price to AUD 3.86 per share for the upcoming fully franked dividend, signalling steady shareholder returns for the half-year ending December 2025.

Sequoia Financial Group has agreed to sell its financial planning arm InterPrac to Conquest Investment Partners for $50,000, following a strategic review that exposed significant challenges and asset write-downs.

Nexsen Limited has successfully completed a pivotal FDA Pre-Submission meeting for its StrepSure® diagnostic, significantly reducing regulatory risks and advancing its entry into the large US maternal health market.

Lindian Resources has operationalised its Tipume Accommodation Camp at the Kangankunde Rare Earths Project, enabling workforce expansion and accelerating construction towards first production in late 2026.